HCA Healthcare, Inc. (HCA) — Fair Value Analysis

Base-case fair value (P50): $413.17 · Current price: $410.50 · Verdict: Fairly Valued

The Verdict on HCA

Based on extensive Monte Carlo simulations, HCA Healthcare (HCA) is currently assessed as Fairly Valued. Our rigorous analysis indicates a median fair value (P50) of $413.17, standing remarkably close to its current trading price of $410.50. This results in a marginal +0.7% against the present market price, reinforcing the verdict that HCA is neither significantly overvalued nor undervalued at this juncture. The proximity of the market price to the P50 fair value suggests that the current consensus effectively discounts HCA's intrinsic worth based on its projected future cash flows and risk profile. Investors looking for substantial immediate upside based purely on this valuation metric might find the opportunity limited.

How HCA stacks up against Healthcare

HCA Healthcare's operational and financial health is categorized as "average" relative to the broader Healthcare sector. This average quality tier aligns directly with its current valuation, where the $410.50 is essentially at parity with our $413.17 fair value. The "average" designation implies that while HCA maintains solid footing, it doesn't present significant competitive advantages or financial outperformance that would warrant a substantial premium above its median fair value. For companies with an average quality tier in the Healthcare sector, finding the market price so closely aligned with the P50 fair value indicates an efficient market assessment of its inherent value.

What this means for investors

For investors, HCA's "Fairly Valued" verdict and "average" quality tier suggest a balanced risk-reward profile, with the $410.50 trading just +0.7% from our $413.17 median fair value. This close alignment might appeal to long-term investors prioritizing stability and fair pricing over speculative growth. While there isn't a significant embedded discount or premium from the median, understanding the full range of potential outcomes, from downside scenarios to more optimistic bull cases, is crucial for comprehensive decision-making. Sign up for a free FairCurve account to access the complete Monte Carlo distribution for HCA, including P10 and P90 targets, and to track its fair value as new financial fundamentals are released.